Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.

In the pivotal Phase 3 VIVID-1 trial, patients treated with Omvoh experienced significant improvement in clinical remission and endoscopic response at one year ...

Eli Lilly's new drug, Omvoh, for example, is an under-the-skin injection that treats ulcerative colitis. Both companies' boards approved the move, Lilly said in its news release.

EXTON, PA, Jan. 31, 2025 (GLOBE NEWSWIRE) -- The FDA's approval of Eli Lilly’s Omvoh for Crohn’s disease marks a significant milestone as the therapy becomes the second IL-23 inhibitor ...

Eli Lilly and Co.’s approval for Omvoh to treat moderate to severe Crohn’s disease in adults marks the Indianapolis company’s growing presence in the treatment of inflammatory bowel disease.

Eli Lilly’s Omvoh (mirikizumab) has been recommended by the National Institute for Health and Care Excellence (NICE) to treat moderately to severely active Crohn’s disease in adults on the NHS in ...

Eli Lilly said it received Food and Drug Administration approval for its treatment for moderate to severely ... Omvoh, was previously approved to treat ulcerative colitis. Skip to Main Content.

First, let's consider how Eli Lilly's newest products will affect its performance in the next half-decade. ... Jaypirca and Omvoh should also contribute meaningfully through the end of the decade.

Eli Lilly will acquire biopharmaceutical firm Morphic Holding in a deal valued at $3.2 billion, both companies announced Monday, a transaction that includes an experimental medication for ...